Actinium Selling General Administrative vs Cost Of Revenue Analysis

ATNM Stock  USD 1.21  0.13  9.70%   
Actinium Pharmaceuticals financial indicator trend analysis is way more than just evaluating Actinium Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Actinium Pharmaceuticals is a good investment. Please check the relationship between Actinium Pharmaceuticals Selling General Administrative and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

Selling General Administrative vs Cost Of Revenue

Selling General Administrative vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Actinium Pharmaceuticals Selling General Administrative account and Cost Of Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Actinium Pharmaceuticals' Selling General Administrative and Cost Of Revenue is 0.57. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Actinium Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Actinium Pharmaceuticals' Selling General Administrative and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Actinium Pharmaceuticals are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Selling General Administrative i.e., Actinium Pharmaceuticals' Selling General Administrative and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.57
Relationship DirectionPositive 
Relationship StrengthWeak

Selling General Administrative

Cost Of Revenue

Cost of Revenue is found on Actinium Pharmaceuticals income statement and represents the costs associated with goods and services Actinium Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most indicators from Actinium Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Actinium Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.At this time, Actinium Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 4th of December 2024, Issuance Of Capital Stock is likely to grow to about 24.8 M, while Enterprise Value Over EBITDA is likely to drop (1.24).

Actinium Pharmaceuticals fundamental ratios Correlations

0.79-0.560.520.86-1.0-0.870.851.01.0-0.510.950.780.910.81.0-0.460.850.750.840.820.830.860.830.96-0.85
0.79-0.380.490.44-0.76-0.810.840.780.78-0.230.840.920.790.930.78-0.160.980.870.980.570.960.90.960.71-0.72
-0.56-0.380.29-0.530.560.35-0.38-0.56-0.560.33-0.52-0.46-0.41-0.37-0.560.3-0.46-0.43-0.45-0.45-0.44-0.42-0.46-0.610.41
0.520.490.290.41-0.53-0.580.590.520.52-0.270.460.430.550.540.52-0.270.460.40.450.530.460.440.430.39-0.46
0.860.44-0.530.41-0.89-0.690.630.870.87-0.460.710.370.750.40.87-0.470.510.340.510.830.460.620.470.83-0.78
-1.0-0.760.56-0.53-0.890.85-0.83-1.0-1.00.51-0.93-0.75-0.9-0.77-1.00.47-0.82-0.72-0.81-0.83-0.8-0.83-0.8-0.950.84
-0.87-0.810.35-0.58-0.690.85-0.94-0.86-0.860.31-0.89-0.72-0.99-0.76-0.860.26-0.84-0.66-0.87-0.76-0.81-0.88-0.83-0.880.95
0.850.84-0.380.590.63-0.83-0.940.840.84-0.270.850.780.920.810.84-0.220.840.690.870.760.830.80.820.8-0.91
1.00.78-0.560.520.87-1.0-0.860.841.0-0.510.940.770.910.791.0-0.460.850.750.830.820.820.850.820.96-0.84
1.00.78-0.560.520.87-1.0-0.860.841.0-0.510.940.770.910.791.0-0.460.850.750.830.820.820.850.820.96-0.84
-0.51-0.230.33-0.27-0.460.510.31-0.27-0.51-0.51-0.45-0.35-0.3-0.36-0.510.99-0.33-0.37-0.29-0.46-0.32-0.35-0.33-0.520.29
0.950.84-0.520.460.71-0.93-0.890.850.940.94-0.450.860.920.870.94-0.380.920.850.90.720.920.910.920.95-0.84
0.780.92-0.460.430.37-0.75-0.720.780.770.77-0.350.860.720.990.77-0.270.950.990.920.50.970.80.960.73-0.58
0.910.79-0.410.550.75-0.9-0.990.920.910.91-0.30.920.720.750.91-0.240.840.670.860.780.810.880.830.92-0.95
0.80.93-0.370.540.4-0.77-0.760.810.790.79-0.360.870.990.750.79-0.290.950.970.930.530.970.810.950.74-0.61
1.00.78-0.560.520.87-1.0-0.860.841.01.0-0.510.940.770.910.79-0.460.840.740.830.820.820.850.820.96-0.85
-0.46-0.160.3-0.27-0.470.470.26-0.22-0.46-0.460.99-0.38-0.27-0.24-0.29-0.46-0.25-0.29-0.22-0.45-0.24-0.28-0.25-0.470.24
0.850.98-0.460.460.51-0.82-0.840.840.850.85-0.330.920.950.840.950.84-0.250.920.990.60.980.941.00.82-0.75
0.750.87-0.430.40.34-0.72-0.660.690.750.75-0.370.850.990.670.970.74-0.290.920.880.440.960.770.940.72-0.5
0.840.98-0.450.450.51-0.81-0.870.870.830.83-0.290.90.920.860.930.83-0.220.990.880.590.960.930.980.8-0.79
0.820.57-0.450.530.83-0.83-0.760.760.820.82-0.460.720.50.780.530.82-0.450.60.440.590.580.70.570.79-0.78
0.830.96-0.440.460.46-0.8-0.810.830.820.82-0.320.920.970.810.970.82-0.240.980.960.960.580.880.990.79-0.7
0.860.9-0.420.440.62-0.83-0.880.80.850.85-0.350.910.80.880.810.85-0.280.940.770.930.70.880.930.86-0.83
0.830.96-0.460.430.47-0.8-0.830.820.820.82-0.330.920.960.830.950.82-0.251.00.940.980.570.990.930.81-0.72
0.960.71-0.610.390.83-0.95-0.880.80.960.96-0.520.950.730.920.740.96-0.470.820.720.80.790.790.860.81-0.85
-0.85-0.720.41-0.46-0.780.840.95-0.91-0.84-0.840.29-0.84-0.58-0.95-0.61-0.850.24-0.75-0.5-0.79-0.78-0.7-0.83-0.72-0.85
Click cells to compare fundamentals

Actinium Pharmaceuticals Account Relationship Matchups

Actinium Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets11.7M66.4M80.4M114.2M81.4M85.5M
Short Long Term Debt Total1.4M738K310K2.6M2.1M2.2M
Other Current Liab4.6M(427K)691K(498K)(541K)(514.0K)
Total Current Liabilities5.3M4.8M6.8M10.6M8.5M4.7M
Total Stockholder Equity5.6M61.3M73.5M66.5M36.4M18.5M
Net Debt(7.8M)(62.8M)(77.5M)(106.3M)(74.6M)(70.8M)
Retained Earnings(208.8M)(231.0M)(255.7M)(288.8M)(337.6M)(320.7M)
Accounts Payable4.6M4.3M5.5M10.1M8.0M8.4M
Cash9.3M63.6M77.8M108.9M76.7M80.5M
Cash And Short Term Investments9.3M63.6M77.8M108.9M76.7M80.5M
Common Stock Total Equity115.7K164.7K18K22K25.3K24.0K
Common Stock Shares Outstanding5.0M12.1M20.6M24.1M26.6M27.9M
Liabilities And Stockholders Equity11.7M66.4M80.4M114.2M81.4M85.5M
Non Current Liabilities Total682.3K311K3K37.1M36.6M38.4M
Other Stockholder Equity214.2M292.3M329.3M355.2M373.9M392.6M
Total Liab6.0M5.1M6.8M47.7M45.1M47.3M
Total Current Assets10.1M64.9M79.7M110.9M78.3M82.2M
Common Stock164.7K18K22K26K28K54.5K
Property Plant And Equipment Net1.1M1.0M639K2.9M2.9M3.0M
Current Deferred Revenue(4.6M)(4.3M)998K35M40.3M42.3M
Non Current Assets Total1.6M1.5M639K3.3M3.2M3.3M
Other Current Assets833.8K1.4M1.9M2.0M1.6M1.2M
Property Plant And Equipment Gross1.1M312K974K3.4M3.6M3.7M
Short Term Debt745.8K854K614K996K1.1M1.1M
Property Plant Equipment1.1M1.0M639K2.9M3.4M3.6M
Net Tangible Assets5.6M61.3M73.5M66.5M76.5M80.3M
Retained Earnings Total Equity(186.9M)(208.8M)(231.0M)(255.7M)(230.2M)(241.7M)
Capital Surpluse195.6M214.2M292.3M329.3M378.7M201.8M
Non Currrent Assets Other49.9K50K(639K)302K313K328.7K
Other Assets441.0K441.2K1.2M302K1.00.95
Net Invested Capital6.0M61.3M73.5M66.5M36.4M41.9M
Net Working Capital4.7M60.2M72.9M100.3M69.8M51.8M
Capital Lease Obligations1.0M738K310K2.6M2.1M1.2M
Capital Stock164.7K18K22K26K28K49.9K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.39)
Revenue Per Share
0.003
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.31)
Return On Equity
(0.88)
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.